Vaxcyte (PCVX) said Wednesday its ongoing phase 2 study assessing VAX-31 for the prevention of invasive pneumococcal disease in infants is advancing to its second and final stage.
The company said participants who received VAX-31 in the first stage will continue the standard dosing regimen as part of the second stage.
Vaxcyte said it expects to release topline data from the study's primary three-dose immunization series in the middle of next year, followed by topline data from the booster dose about nine months later.
In infants, the VAX-31 was designed to cover about 94% of invasive pneumococcal disease and roughly 93% of acute otitis media caused by streptococcus pneumoniae in children under five years old in the United States.
Shares of Vaxcyte were up nearly 3% in recent trading.
Price: 88.88, Change: +2.37, Percent Change: +2.73
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.